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Members of the NF-kB/Rel transcription factor family
have been shown recently to be required for cellular
transformation by oncogenic Ras and by other oncopro-
teins and to suppress transformation-associated apopto-
sis. Furthermore, NF-kB has been shown to be activated
by several oncoproteins including HER2/Neu, a receptor
tyrosine kinase often expressed in human breast cancer.
Human breast cancer cell lines, human breast tumors
and normal adjacent tissue were analysed by gel mobility
shift assay, immunoblotting of nuclear extracts and
immunohistochemistry for activation of NF-kB. Further-
more, RNA levels for NF-kB-activated genes were
analysed in order to determine if NF-kB is functionally
active in human breast cancer. Our data indicate that the
p65/RelA subunit of NF-kB is activated (i.e., nuclear) in
breast cancer cell lines. However, breast tumors exhibit
an absence or low level of nuclear p65/RelA but show
activated c-Rel, p50 and p52 as compared to nontumori-
genic adjacent tissue. Additionally, the IkB homolog Bcl-
3, which functions to stimulate transcription with p50 or
p52, was also activated in breast tumors. There was no
apparent correlation between estrogen receptor status
and levels of nuclear NF-kB complexes. Transcripts of
NF-kB-regulated genes were found elevated in breast
tumors, as compared to adjacent normal tissue, indicat-
ing functional NF-kB activity. These data suggest a
potential role for a subset of NF-kB and IkB family
proteins, particularly NF-kB/p52 and Bcl-3, in human
breast cancer. Additionally, the activation of functional
NF-kB in these tumors likely involves a signal
transduction pathway distinct from that utilized by
cytokines. Oncogene (2000) 19, 1123 – 1131
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Introduction
As with virtually all malignancies, breast cancer is
associated with dysregulated expression of growth
factors and growth factor receptors as well as kinases
associated with growth factor signaling pathways
(Dickson and Lippman, 1995; Resnik et al., 1998).
The ultimate downstream eectors of these pathways
are transcription factors. Thus, dysregulated transcrip-
tion is likely to play an important role in cancer since it
has been shown that the transcription factors c-jun, ets,
c-myc and NF-kB are each required for cellular
transformation controlled by oncogenic Ras alleles
(Johnson et al., 1996; Langer et al., 1992; Sklar et al.,
1991; Finco et al., 1997). The ultimate gene targets of
these transcription factors that contribute to oncogen-
esis are poorly understood.
NF-kB is a transcription factor that is known to
play an important role in controlling immune and
inflammatory responses (see Baldwin, 1996; Ghosh et
al., 1998; Verma et al., 1995). There are presently five
members of the mammalian NF-kB/Rel family: NF-
kB/p50, NF-kB2/p52, c-Rel, RelA/p65 and RelB. The
p50 and p52 NF-kB subunits are derived from larger
precursor products, p105 and p100 respectively, or
from dierential translation of their mRNAs. The
classic form of NF-kB, the heterodimer of the p50 and
65 subunits, is normally retained in the cytoplasm
through interactions with inhibitor proteins IkBa and
IkBb. Inductive stimuli (TNFa, IL-1, bacterial en-
dotoxin, etc.) lead to the phosphorylation and
degradation of IkB, allowing NF-kB to enter the
nucleus and regulate gene expression (reviewed in
Baldwin, 1996; Ghosh et al., 1998; Verma et al.,
1995). IkBa is inducibly phosphorylated on serines 32
and 36 following activation of the IkB kinase complex
(Ghosh et al., 1998). Following its degradation, IkBa is
transcriptionally upregulated due to NF-kB sites in its
promoter which leads to a suppression of p65- and c-
Rel-containing heterodimers. IkBb also interacts with
the same heterodimers as IkBa but is degraded with
slower kinetics and functions in the persistent activa-
tion of NF-kB (Ghosh et al., 1998). Bcl-3, a
noninhibitory member of the IkB family (Ohno et al.,
1990; Kerr et al., 1992) that is associated with certain
leukemias and lymphomas (McKeithan et al., 1997),
functions to stimulate transcription through interac-
tions with the p50 or p52 NF-kB subunits (Bours et al.,
1993; Fujita et al., 1993) and to increase nuclear levels
of p50 homodimers (Zhang et al., 1994; Watanabe et
al., 1997). Bcl-3-p50 complexes can be activated
following inducible phosphorylation of the p105
precursor by the IkB kinase (Heissmeyer et al., 1999).
Recently, it was shown that Bcl-3 interacts with
transcriptional co-activators, including the Tip60
histone acetyltransferase (Dechend et al., 1999). Gene
knockout studies confirm the important roles of the
NF-kB family in immune function and also indicate
that the RelA/p65 subunit is required to suppress liver
cell apoptosis (reviewed in Baldwin, 1996; Ghosh et al.,
1998; Verma et al., 1995; and see Beg et al., 1995).
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Additionally we, Wang et al. (1996), and others
(Arsura et al., 1996; Beg and Baltimore, 1996; Liu et
al., 1996; Van Antwerp et al., 1996; Chu et al., 1997),
have shown that NF-kB suppresses apoptosis initiated
by tumor necrosis factor, chemotherapy or radiation.
Evidence for a role of NF-kB in oncogenesis is
extensive. The founding member of the NF-kB family,
c-Rel, is the cellular homolog of v-Rel, the transform-
ing gene of avian reticuloendotheliosis virus (Gilmore,
1997). One of the NF-kB genes, NF-kB2/p52 (lyt-10),
is found translocated in some lymphoid neoplasms
(Chang et al., 1995) as is the IkB family member Bcl-3
(McKeithan et al., 1997; Michaux et al., 1997).
Furthermore, several oncoproteins, including HER2/
Neu, Ras and Bcr-Abl, are known to activate NF-kB
and NF-kB is required for transformation induced by
Ras and by Bcr-Abl (Galang et al., 1996; Finco et al.,
1997; Reuther et al., 1998). Importantly, NF-kB
activation suppresses a transformation-induced apop-
tosis associated with oncogenic Ras expression (Mayo
et al., 1997) and expression of the RelA/p65 subunit is
required for growth of Hodgkin’s lymphoma (Bargou
et al., 1997). Consistent with this, IkBa is found
mutated in certain cases of Hodgkin’s disease (Ca-
bannes et al., 1999). Recently, it was shown that NF-
kB transcriptionally regulates the gene encoding cyclin
D1 and, correspondingly, promotes cell growth (Hinz
et al., 1999; Guttridge et al., 1999).
NF-kB expression has been analysed in human
breast cancer cell lines and in breast cancer tissue.
Dejardin et al. (1995) found that the 100 kD precursor
of the NF-kB2/p52 subunit was overexpressed in a
majority of breast cancer samples and in cancer cell
lines, suggesting a role for the precursor in retaining
classic forms of NF-kB in the cytoplasm. Nakshatri et
al. (1997) found that NF-kB RelA/p65 is activated (i.e.,
nuclear) in the majority of human breast cancer cell
lines and that the relative level of NF-kB was inversely
correlated with estrogen receptor (ER) expression.
Recently, Sonenshein and colleagues (Sovak et al.,
1997) found increased levels of NF-kB in human breast
cancer samples and that inhibition of NF-kB in a
breast cancer cell line led to apoptosis. We have
explored the NF-kB subunit composition in human
breast tumors and have found that the p50, p52, and c-
Rel subunits are found in the nucleus in virtually all
samples of breast cancer. Importantly, the p52 subunit
was significantly upregulated in tumor tissue as
compared to stromal fibroblasts or adjacent, non-
tumor breast epithelium. There was no apparent
correlation between ER status and NF-kB activation
in the tumor samples. Interestingly, the p65 subunit
was activated in breast cancer cell lines but was not
activated to a significant level in breast cancer.
Furthermore, the IkB homolog Bcl-3, which has been
shown to function with p50 and p52 subunits to
stimulate transcription (Bours et al., 1993; Fujita et al.,
1993) and which is associated with leukemia
(McKeithan et al., 1997; Michaux et al., 1997), was
also found to exhibit increased nuclear levels in human
breast cancer as compared to non-tumor tissue but was
not increased in human breast cancer cell lines.
Consistent with these observations, transcripts of
known NF-kB-regulated genes were found to be
significantly elevated in human breast cancer tissue.
These data indicate that NF-kB is functionally active
in human breast cancer and that a subset of NF-kB
complexes, which do not include the p50/p65 hetero-
dimer, is activated in human breast cancer. Further-
more, the results suggest that non-typical mechanisms
are involved in activation of functional NF-kB in
breast cancer.
Results
NF-kB binding activity is increased in breast cancer cell
lines
In many instances the utilization of immortalized or
transformed cell lines is widely recognized as an
appropriate model to test the function of a particular
transcription factor. In order to determine whether
NF-kB plays a role in breast cancer, we examined
several breast cancer cell lines for the activation of NF-
kB. Activation of NF-kB is characterized by an
increase in nuclear NF-kB, an event that can be
monitored through electrophoretic mobility shift assays
(EMSAs). We analysed five well characterized breast
cancer cell lines: MCF7, T47D, MDA231, SKBR3 and
BT474. Nuclear extracts from each of these cell lines
were incubated with a radiolabeled oligonucleotide
probe containing an NF-kB DNA binding site.
Nuclear extracts from SKBR3 cells contain the
strongest NF-kB binding complex followed by
BT474, MDA231 and MCF7 (Figure 1a). Nuclear
extracts from T47D cells contain very little NF-kB
DNA binding activity. Similar data were obtained
using dierent nuclear extract preparations (data not
shown). To identify which NF-kB components con-
tribute to this binding activity, we performed supershift
analysis with NF-kB specific antibodies. An antibody
Figure 1 Analysis of NF-kB in human breast cancer cell lines.
(a) EMSAs were performed with nuclear extracts prepared from
MDA231, MCF7, BT474, SKBR3 and T47D breast cancer cell
lines. Nuclear extracts (5 mg) were incubated with a 32P-labeled
oligonucleotide probe containing an NF-kB binding site (see
Materials and methods section), and complexes were resolved on
a 5% nondenaturing polyacrylamide gel. NF-kB complexes I and
II are indicated with arrows. The estrogen receptor (ER) status of
each cell line is indicated below each line. (b) Supershift analysis
was performed by preincubating nuclear extract prepared from
the SKBR3 cell line with various NF-kB/Rel specific antibodies
for 15 min prior to the addition of the oligonucleotide probe.
Arrows placed on the right side of the panel indicate supershifted
complexes
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specific for the p65 subunit of NF-kB, which can
recognize p65 homodimers and p50/p65 heterodimers
of NF-kB, supershifted complex I and was unable to
shift complex II (Figure 1b). However, both complexes
I and II are supershifted when a p50 antibody, which
recognizes both p50 homodimers and p50/p65 hetero-
dimers, and when a p52 antibody were used. When an
antibody specific for c-Rel is added to the binding
reaction there appears to be a decrease in DNA
binding but no visible supershift complex is formed.
The relative lack of c-Rel binding is not due to the
oligonucleotide probe favoring binding of p65 over
that of c-Rel, since nuclear extracts prepared form
WEHI-231 cells, known to contain high levels of c-Rel
binding activity, show that the probe is readily bound
by c-Rel (data not shown). These data suggest that
there is an increase in NF-kB DNA binding complexes
in nuclear extracts of breast cancer cell lines. The
greatest NF-kB binding activity occurs with complexes
containing the p65 subunit of NF-kB, a classic NF-kB
component.
A recent study demonstrated that estrogen receptor
(ER) negative breast cancer cell lines contain an
increase in constitutive NF-kB DNA binding when
compared to ER-positive cell lines (Nakshatri et al.,
1997). In our study we find that the ER negative
SKBR3 cell line does show the greatest NF-kB binding
complexes (Figure 1), however NF-kB binding com-
plexes formed in the ER-positive cell line BT474 are
only slightly lower. In addition, by Western analysis,
the ER positive cell line MCF-7 appears to have the
highest expression of both p65 and c-Rel proteins (data
not shown). We have also observed by Western
analysis that the ER-positive T47D cell line, which
has very little NF-kB binding activity, appears to have
p65 and p105 of slightly altered mobility (data not
shown and see Figure 4b). The altered protein
expression in these cells may contribute to the lack of
NF-kB DNA binding observed in EMSA (Figure 1b),
and probably has nothing to do with the ER status in
that cell line. The fact that we do not observe a strong
correlation with NF-kB and ER activity in these cell
lines may be due to the fact that cell lines carried in
culture can show great dierences in the amount of
NF-kB present over time. In addition, slight changes in
culture media and the source of the original cell may
also contribute to these dierences.
Primary tumor cells from patients with breast cancer
exhibit increased NF-kB binding activity
Although we have analysed NF-kB DNA binding in
breast cancer cell lines, we were interested in determin-
ing the status of NF-kB activity in cells from primary
breast tumors. Seventeen cases of carcinomas of the
breast were received from Lineberger Comprehensive
Cancer Tissue Procurement files. Sixteen were primary
breast carcinomas, and one was a local recurrence.
Twelve cases were pure ductal, ranging in size from
0.4 – 9 cm in diameter and ranging from grade 1 – 3. Of
these cases for which steroid receptor data are
available, 3/8 were ER positive and 3/6 were PR
positive. Two cases were mixed ductal and lobular,
ranging in size from 0.4 – 5 cm and ranging from grade
1 – 2. Of the cases of this group for which steroid
receptor data are available, 2/2 were ER positive and
2/2 were PR positive. Two cases were pure lobular,
ranging in size from 1.7 cm to diuse (420 cm) and
ranging from nuclear grade 1 – 2. Of these cases for
which steroid receptor data are available, 1/2 were ER
positive, and 1/2 were PR positive.
Nuclear extracts from snap frozen tissue sections of
primary breast tumors and normal adjacent breast
tissue were obtained from nuclei isolated by sucrose
pad purification. EMSAs were performed on nuclear
extracts and DNA binding activity between tumor (T)
and adjacent tissue (A) was analysed. The results show
that all tumor samples contain NF-kB specific DNA
binding activity (Figure 2a). Although patient 1
appears to have the highest level of NF-kB binding
activity, all seven patients show a dramatic increase in
NF-kB DNA binding complexes when compared to
their nontumorigenic adjacent tissue. Although the
absolute levels of NF-kB binding activity vary between
tumorigenic patient samples, all have correspondingly
higher binding activity than their adjacent tissue
(Figure 2a). The level of NF-kB binding does not
appear to be related to the estrogen receptor status
since both ER+ and ER7 samples exhibit high levels
of NF-kB binding (Figure 2a).
To identify which components of NF-kB contribute
to this binding activity, supershift analysis was
performed with nuclear extracts from patient 7 (Figure
2b). Supershift analysis identified p50, p52 and c-Rel as
the predominant NF-kB subunits contained in these
binding complexes (Figure 2b). It is noted that these
antibodies do not strongly reduce the major DNA/
protein complex, which may be due to an opposing
stabilization of the complex by the immune serum or to
the inability of the complex to be eciently recognized
by the antiserum. It also remains possible that an
additional, uncharacterized subunit is part of the major
DNA binding activity. Antibodies to RelB did not
aect the DNA/protein complex (data not shown).
Surprisingly when a p65 specific antibody which
recognized both p65 homodimers and p50/p65 hetero-
dimers was added to the binding reaction only the very
faint upper complex seen is supershifted. This complex
appears in only three of the 17 patient samples
analysed and thus does not appear to be an important
factor in the overall upregulation of NF-kB activity in
primary breast tumor cells. The DNA binding activity
obtained with tumor nuclear extracts is specific as
shown by competition with the cold probe (UV21) and
with a shorter, commercially available consensus NF-
kB oligonucleotide (Figure 2c). The EMSA complexes
detected with breast cancer nuclear extracts do not
appear to contain NF-kB binding complexes identified
as complex I in breast cancer cell lines, since the
tumor-derived DNA-protein complexes are faster
migrating than the predominant p50/p65 heterodimer
complex found in the cell lines (see Figure 2c). From
these results we conclude that the increase in NF-kB
DNA binding present in the nuclear extracts from
breast tumor cells appears to represent an increase in
p50, p52 and c-Rel but not p65. Similar results were
obtained in all tumor and adjacent samples tested (data
not shown). In order to confirm the statistical
significance of our previous result, EMSAs were
performed on additional patient tumor samples. The
results from these patients demonstrate that NF-kB
DNA activity is elevated in 10/10 breast tumors
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examined (data not shown). Thus, we have examined
tumors from 17 patients and every patient sample
exhibited an increase in NF-kB binding activity.
Surprisingly, these NF-kB complexes do not involve
significant levels of p65, the most commonly analysed
NF-kB component. Although a few patients (3/17)
showed an increase in p65 binding activity in breast
tumors, the level of binding is significantly less than
exhibited by the major complex. These data indicate
that NF-kB family members other than p65 are
upregulated in breast tumors.
Immunohistochemistry indicates an increase in
p50/NF-kB1, p52/NF-kB2, and c-Rel proteins in
breast tumors
To initially determine if p50, p52 and c-Rel are present
at higher levels in breast tumor samples as compared
to their normal adjacent tissues, immunohistochemistry
was performed using NF-kB specific on paran
embedded sections of normal and tumorigenic breast
tissue from patients 1 and 2. The results shown in
Figure 3 are from patient 1 and demonstrate an
increase in p52 and c-Rel protein levels in breast
tumors when compared to nontumorigenic adjacent
tissue. The increased staining for c-Rel appears to be in
the infiltrating ductal regions as well as in the
surrounding stromal cells indicating an overall increase
in staining in the tumor section. However, the staining
for p52 is specifically increased in the cancerous ductal
regions of the tumor section, with very little staining
observed in the stromal cells, suggesting that the
increase in p52 protein is seen primarily in the cancer
cells. There is also an increase in staining in the tumor
samples when compared to adjacent tissue using the
p50 specific antibody. Staining with an antibody for
the p65 subunit of NF-kB indicates that there is some
dierence in p65 protein levels between adjacent and
tumor tissue. To determine whether the staining seen
with the p65 antibody is nuclear, an antibody specific
for the activated form of p65 (p65-NLS, which
recognizes p65 released from IkB) was utilized and
no antibody specific staining in either the adjacent or
tumor sections is detectable (data not shown). There-
fore, breast cancer tissues contain increased NF-kB
involving the NF-kB subunits p50, p52, and c-Rel. The
upregulation of p52 appeared to be more specific for
tumor cells. Because of the large quantity of
cytoplasmic staining for each of the samples and the
high background with some of the antibodies, it is
dicult to determine whether there is a corresponding
increase in nuclear staining, thus we have directly
measured nuclear levels of NF-kB subunits. Addition-
ally, the immunohistochemistry does not distinguish
between expression of the precursor forms (p100 and
p105) and the processed forms (p50 and p52) of these
NF-kB sunumits.
NF-kB subunits p50, p52 and c-Rel as well as Bcl-3 are
increased in nuclei of breast cancer cells
To correlate the increases in p52, p50 and c-Rel seen in
EMSA and in the immunohistochemistry experiments
with actual protein levels, Western blot analysis was
performed using the nuclear extracts examined in Figure
2. Nuclear proteins were electrophoresed on an SDS
Figure 2 NF-kB DNA binding activity is elevated in breast
tumors. (a) EMSAs were performed on nuclear extracts prepared
from sucrose pad-purified nuclei from frozen tissue obtained in
seven patients with breast cancer. Equivalent amounts of protein
(2 mg) were used to identify DNA binding activity in tumor (T)
when compared to normal adjacent tissue (a). Nuclear extracts
were incubated with a 32P-labeled oligonucleotide probe contain-
ing an NF-kB binding site. (b) Supershift analysis was performed
on nuclear extracts isolated from tumor samples of patient 7.
Extracts were preincubated for 15 min with NF-kB/Rel specific
antibodies prior to the addition of probe. Upper arrows indicate
supershifted complexes. (c) Competition analysis (left panel) was
performed with cold, excess UV21 probe or with a commercially
available NF-kB oligonucleotide as indicated at the top). EMSAs
(right panel) were performed to compare mobilities of NF-kB
complexes from breast cancer cell lines (labeled at the top) or
from the breast tumor from patient 2. Complexes I and II are
indicated
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polyacrylamide gel, transferered to membrane and
probed with a panel of NF-kB specific antibodies. The
results are shown in Figure 4a. An increase in nuclear
p50, p52, and c-Rel protein levels is observed in each
tumor sample when compared to adjacent nontumori-
genic tissue. In agreement with our EMSA data, there
was little detectable p65 protein present in either the
adjacent or tumor nuclear samples from these patients.
The p65 protein was not degraded in these extracts as
cytoplasmic p65 was readily detectable by immunoblot-
ting (data not shown). An antibody specific for human a-
actin was used to control for equal loading. This data
again diers from data obtained with breast tumor cell
lines which show a significant increase in p65 protein in
Western analysis (see below).
Both p50 and p52 proteins appear to be normally
transcriptionally inactive, except when found in a
complex with the IkB homolog Bcl-3 (Bours et al.,
1993; Fujita et al., 1993). Therefore, we probed the
breast cancer nuclear extracts for Bcl-3. As shown in
Figure 4a, Bcl-3 was found to be significantly elevated
in the nuclear extracts of each of the tumor samples
analysed as compared to the normal adjacent tissue.
These results provide a potential mechanism to explain
transcriptional activity associated with nuclear levels of
p50 and p52 (see below and see Discussion). In
Figure 3 Immunohistochemistry analysis of breast tumor tissue for NF-kB. Sections of paran-embedded tumor (T) and normal
adjacent tissue (A) from patient 1 were probed with p65, p50, p52 or c-Rel specific antibodies, and bound antibodies were visualized
using immunoperoxidase detection. Following antibody specific staining, sections were counterstained with hematoxylin
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contrast with the breast tumors, nuclear extracts
derived from breast cancer cell lines exhibit elevated
nuclear levels of p65 and p50, but variable expression
of p52 and c-Rel (Figure 4b). As described above, there
is a slower mobility of the p65 found in T47D (Figure
4b) that is apparent on longer gel migration.
Additionally, breast cancer cell lines exhibited virtually
no nuclear Bcl-3 (Figure 4b) which was due to low
levels of Bcl-3 mRNA expression (data not shown).
Activation of NF-kB regulated genes in tumorigenic tissue
samples
Many of the NF-kB and IkB genes are known to be
regulated by NF-kB, thus allowing for the assay of
potentially increased kB-dependent gene expression in
breast cancer. Thus, the p50 and p52 genes, but not the
gene encoding p65, are known to be regulated by NF-
kB (see Baldwin, 1996; Liptay et al., 1994). In order to
determine whether the increase in p50 and p52 levels
observed in breast cancer tumor tissue was due to an
increase in mRNA, additional tumor samples were
obtained and RNA analysis was performed. Enzymatic
amplification by PCR is well suited for RNA analyses
in this study because the limited sample amount that
we were able to obtain was insucient for more
standard methods of analysis. Using the reverse
transcriptase-polymerase chain reaction (RT –PCR)
under limiting conditions, we generated amplified
products which were electrophoresed on agarose gels.
Amplified DNA levels were quantified by Southern
analysis. As shown in Figure 5, an increase in mRNA
from the p50 and p52 genes is observed in tumor tissue
when compared to mRNA levels for these genes in
adjacent tissue. Additionally, a dramatic increase in
mRNA from the IkBa gene, which is known to be
regulated by NF-kB (Baldwin, 1996; Ghosh et al.,
1998), was observed in tumor samples. Presumably, the
Figure 4 Levels of nuclear NF-kB proteins are elevated in breast
tumors. (a) Nuclear extracts (24 mg) of tumors or of adjacent
tissue from patients 4 – 7 (see Figure 1) were analysed by Western
blot analysis. Proteins were fractionated on SDS polyacrylamide
gels, transferred to nitrocellulose and incubated with antibodies
specific for p65, p50, p52, c-Rel and Bcl-3. Normal adjacent tissue
(A) and tumor tissue (T) are indicated for each patient. Blots were
normalized to the level of a-actin protein. (b) Nuclear extracts of
breast cancer cell lines were analysed by Western blot analysis for
expression of the proteins shown part A. The Bcl-3 blot contained
a tumor extract (T) and extracts from a 3T3 cell line expressing
Bcl-3 (+) as positive controls
Figure 5 Increased mRNA levels of p52, p50, IkB, Bcl-3 and
cyclin D1 but not p65 are seen in breast tumors. Total RNA
(4 mg) was isolated from tumor and normal adjacent tissue of
patients 1 and 7. RT–PCRs were performed to generate partial
cDNA transcripts encoding the NF-kB family members p65, p50
and p52 as well for Bcl-3, cyclin D1, IkBa and a-actin. RT–PCR
products were resolved on agarose gels and detected via Southern
blotting using independently derived cDNA probes. Products
were amplified 25 cycles with the exception of p65 which required
an additional ten cycles for visualization. Exposure times for
Southern blots ranged from 24 – 48 h. In all cases, RT–PCR
products were of the size predicted by their nucleotide sequences
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NF-kB forms activated in breast cancer can activate
expression of the IkBa gene. Interestingly, upregulation
of IkBa presumably would not aect the nuclear
accumulation of p50 and p52 complexes. When oligos
specific for p65 were used, an additional ten PCR
cycles were necessary in order to visualize any product
by Southern analysis. Consistent with our previous
findings, there was no increase in p65 mRNA between
adjacent and tumor tissue. Additionally, mRNA levels
for Bcl-3, which contains NF-kB binding sites in its
promoter region (see Ohno et al., 1990), and for cyclin
D1 are elevated in breast tumor tissue as compared to
adjacent tissue. Cyclin D1 was recently shown to be
transcriptionally regulated by NF-kB (Hinz et al.,
1999; Guttridge et al., 1999). The normalization using
human a-actin shows equal PCR products for each
sample. This data suggests that the increase in protein
seen in Western analysis for p50, p52 and Bcl-3 is
caused by an increase in mRNA level due to either the
stabilization of the mRNA or, more likely, to an
increase in transcription of the NF-kB regulated genes
likely through the activation of functional NF-kB
activity. The potential regulation of cyclin D1 gene
expression in human breast cancer by NF-kB/Bcl-3
complexes is important since cyclic D1 protein
expression is unregulated in the great majority of
breast tumors. Preliminary data indicate that cyclin D1
can be transcriptionally activated by p50 plus Bcl-3 (S
Westerheide and AS Baldwin Jr, in preparation).
Discussion
The results we obtained through EMSA and Western
analysis of nuclear extracts isolated from patients with
breast cancer along with immunohistochemical studies
revealed a distinct pattern of activation of NF-kB
subunits as compared to normal, adjacent tissue.
Additionally, a dierent pattern of NF-kB expression
was found from that seen in commonly used breast
cancer cell lines and from that seen following treatment
of cells with cytokines or other NF-kB inducers. Thus,
breast cancer cell lines exhibit a constitutive level of NF-
kB activation that consists primarily of the p50/p65
heterodimer and of the p50 homodimer. Consistent with
these findings, we have made the observation that long-
term culture of a variety of cell lines leads to increased
levels of nuclear NF-kB consisting of the p65 subunit
(data not shown). However, our data indicate that NF-
kB binding complexes containing p50, p52 and c-Rel are
activated (i.e., nuclear) in human breast cancers without
a corresponding consistent activation of the p65 subunit.
Similar to our studies, Sovak et al. (1997) found that two
of five breast tumor samples exhibited significant p65
nuclear expression. With respect to NF-kB and its
potential biological role in breast cancer, our results
demonstrate that established breast cancer cell lines may
not serve as a completely reliable model for this disease.
Increases in p50, p52 and c-Rel levels and binding
activities are detected in breast tumors as compared to
non-tumorigenic adjacent tissue. Interestingly, immu-
nohistochemical approaches show a dramatic quanti-
tative increase of p52 in the ductal regions of the breast
cancer and not in the invading stromal fibroblasts
(Figure 3). Previously, it was shown that cellular levels
of the 100 kD precursor of p52 were elevated in a
majority of breast cancer samples (Dejardin et al.,
1995). However, corresponding nuclear levels of p52
were not analysed in these primary samples. Although
c-Rel is known to harbor transcriptional activation
domains, both the p50 and p52 subunits have not been
shown to be transcriptionally active unless complexed
with the IkB homolog Bcl-3 (Bours et al., 1993; Fujita
et al., 1993; Schmid et al., 1994). Consistent with this
concept, the phenotype of the Bcl-3 knockout overlaps
significantly with that of the p50 and the p52
knockouts (Caamano et al., 1998; Franzozo et al.,
1997, 1998; Schwarz et al., 1997). Importantly, we find
that Bcl-3 nuclear levels are increased in breast cancer
tissue as compared to the adjacent levels, which is
interesting since it was published recently that Bcl-3
can function to increase nuclear levels of p50 (Zhang et
al., 1994; Watanabe et al., 1997). Thus, an increase in
nuclear Bcl-3 may function with increased levels of p50
and p52 to account for the enhancement in NF-kB
dependent gene expression observed in human breast
cancer (Figure 5). Since p50 and p52 are not thought
to be directly regulated through complexes with IkBa
or IkBb, our data suggest that a pathway is active in
breast cancer that functions to increase levels of certain
forms of NF-kB that is independent of the normal
inductive pathways that involves degradation of one of
the IkB subunits. However, we cannot rule out that the
increase in nuclear levels of c-Rel found in breast
cancer is controlled through a pathway that involves
release from a form of IkB. Our data also indicate that
levels of mRNAs for p50 and p52 are increased in
breast cancer, likely through the transcriptional
activation of these genes by active NF-kB complexes
(Baldwin, 1996; Ghosh et al., 1998; Liptay et al., 1994).
This is likely to contribute to the increase in these NF-
kB subunits in breast cancer. Additionally, increased
mRNA levels for Bcl-3 were observed in breast tumors.
However, Bcl-3 levels were barely detectable in nuclear
or cytoplasmic extracts of breast cancer cell lines and
Bcl-3 mRNA levels were relatively low.
Of the NF-kB subunits found activated in human
breast cancer, c-Rel and p52 each have been implicated
with oncogenesis (Baldwin, 1996; Gilmore, 1997; Chang
et al., 1995). The p100/p52 gene is found translocated
and rearranged in certain lymphomas such that it is
overexpressed without the normal ankyrin repeats.
Removal of the C-terminal ankyrin repeats of p100/p52
leads to gastric hyperplasia and to enhanced proliferative
responses of lymphocytes (Ishikawa et al., 1997). c-Rel
can be transforming when mutated and expressed in
retroviral form (Gilmore, 1997) and IkBa expression can
delay tumor formation in v-Rel expressing mice
(Carrasco et al., 1997). Importantly, we find that Bcl-3
nuclear levels are increased in human breast cancer and
Bcl-3 has also been found translocated [t(14;19)] and
overexpressed in certain B-cell lymphomas (McKeithan
et al., 1997; Michaux et al., 1997). Consistent with a role
for Bcl-3 in human leukemia, it was found that Bcl-3
transgenic mice exhibit lymphadenopthy and splenome-
galy (Ong et al., 1998).
What is the possible role for elevated NF-kB
functional activity in human breast cancer? Our recent
data indicated that NF-kB activation suppresses a
transformation-associated apoptosis (Mayo et al.,
1997). Thus, NF-kB may serve to suppress a similar
apoptosis in developing breast cancer. Consistent with
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this, Sonenshein and colleagues (Sovak et al., 1997)
found that inhibition of NF-kB in a breast cancer cell
line led to enhanced cell death. Future experiments will
determine if the forms of NF-kB that are activated in
human breast tumors provide a cell survival function in
the tumor tissue and can activate genes known to
suppress apoptosis. This process may also contribute to
chemoresistance of breast tumors. Additionally, our
recent data and that of others indicates that NF-kB
can promote cell cycle progression through the
activation of cyclin D1 promoter activity (Hinz et al.,
1999; Guttridge et al., 1999) and, thus the activation of
NF-kB functional activity may promote the enhanced
cell proliferation and overexpression of certain cyclins
that are characteristic of breast cancer (Sherr, 1996).
Materials and methods
Cell culture
All cell lines were obtained from the Lineberger Comprehen-
sive Cancer Center Tissue Culture Core Facility at the
University of North Carolina, Chapel Hill. MCF-7 cells were
maintained in DMEM, T47D cells were grown in RPMI 1640
medium containing 16 ITS (insulin-transferrin-sodium
selenite; Boehringer Mannheim), BT474 cells were cultured
in EMEM with ITS, MDA231 cells were grown in Iscoves
medium, and SKBR-3 cells were grown in Macoys5A
medium. Growth media contained antibiotics and 10% fetal
calf serum obtained from Life Technologies.
Tissue samples
Lumpectomy and mastectomy samples from breast cancer
patients were separated into tumor tissue and normal
adjacent tissue by a pathologist. Samples were either quickly
snap frozen in liquid nitrogen, or directly embedded in
paran. A total of 17 samples were obtained, of which seven
were matched sets of both tumor and normal breast tissue as
determined by histological analysis.
Cell extracts and Western blotting
Nuclear extracts from each cell line were prepared as
previously described (Finco et al., 1997). Nuclear extracts
from snap frozen tissue sections were prepared by resuspend-
ing crushed, frozen samples in sucrose buer (0.3 M sucrose,
60 mM KCl, 15 mM NaCl, 15 mM HEPES pH 7.5, 2 mM
EDTA, 0.5 mM EGTA, 14 mM b-mercaptoethanol and 0.1%
NP40) followed by dounce homogenization. Nuclei were
isolated following double sucrose pelleting through 0.88 M
and 1 M sucrose solutions. For Western blotting analysis,
equal amounts of protein were separated on an 8% SDS-
polyacrylamide gel and transferred to nitrocellulose. Blots
were blocked in 5% milk in 16 TBST (Tris Buered Saline,
0.5% Tween 20) and probed with either anti-p50, anti-Bcl-3,
anti-a-actin (Santa Cruz Biotechnology), anti-p65 (Rock-
land), or anti-p52 (Rockland) each at 1 : 1000 dilution in 16
TBST. Blots were probed with a secondary antibody
conjugated to horseradish peroxidase (Promega Corp.) at
1 : 10 000 dilution in 16 TBST. Protein bands were visualized
with an enhanced chemiluminescence detection system
(Amersham Life Science).
Electrophoretic mobility shift assay (EMSA)
EMSAs were performed as described previously (Mayo et al.,
1997). An oligonucleotide corresponding to an NF-kB site in
the H-2Kb gene (5’-CAGGGCTGGGGATTCCCATCTCC-
CACAGTTTCACTTC-3’) was radiolabeled using a-32P-
dCTP and the Klenow fragment of DNA polymerase I
(Boehringer Mannheim). For antibody supershift analysis,
nuclear extracts were preincubated 15 min at room tempera-
ture with 1 mg antiserum before the addition of the
radiolabeled gel shift probe. Antibodies used in supershift
analysis are identical to those utilized for Western blotting
described above.
Immunohistochemistry
Formalin-fixed, paran-embedded tissues were cut to 4 mm,
and sections were deparanized in xylene, rehydrated, and
probed using specific NF-kB/Rel antibodies (listed above for
Western blotting). Staining was performed using the
Vectastain ABC immunoperoxidase staining kit in conjuga-
tion with 3’,3’-diaminobenzidine (Vector Labs). Tissues were
counterstained with Mayer’s hematoxylin (Sigma), overlaid
with permount mounting solution (Fisher Scientific) and
placed under coverslips.
RT–PCR
Snap frozen tissue sections were homogenized in 4 M
guanidinium isothiocyanate using a Brinkman Polytron
(Westbury). RNA was then isolated by centrifugation
through 5.7 M cesium chloride. To produce cDNA, total
RNA (4 mg) and random hexamers (200 ng; Life Technolo-
gies were dentured at 808C for 10 min and incubated for
60 min at 378C in first strand synthesis buer containing
10 mM DTT (Life Technologies), with 625 mM dNTP
(Boehringer Mannheim), and 400 units of MMLV reverse
transcriptase (Life Technologies). Resulting cDNAs were
diluted 1 : 5 in dH20 and an aliquot was combined with a
mixture containing 200 nM of specific oligonucleotides,
250 mm dNTP, 1.5 mM magnesium chloride, 16 PCR buer,
and 2.5 units of Taq polymerase (Life Technologies). Cycle
conditions were the following: denaturation, 948C for 30 s;
annealing, 588C for 30 s; and extension, 728C for 1 min. The
amount of input cDNA was adjusted first to obtain equal
amounts of a-Actin product. Amplified products ranged from
450 – 550 bp in length. Forward (1) and reverse (2) primers
used for RT–PCR were the following: p65-1, 5’-
CGTGGAGGTGTATGATGATGACGTA-3’; p65-2, 5’-CT-
AGAATCTAGCTGGAGGGAGGCCA-3’, p50-1, 5’-TGG-
ATCCTTCTTTGACTCATACAAT-3’; P50-2, 5’-GTCTGC-
TGCAGAGCTGCTTGGCGGA-3’; IkBa-1, 5’-GGGACCC-
TCAGCAGAGAGGAGGACC-3’; IkBa-2, 5’-GCTTTCA-
GTTGTTGTGATGCTGAGA-3’; cyclinD1-1, 5’-ACCCGG-
CCTGCTTCCACC; cyclinD1-1, 5’-GCTGCCTCCTGGAG-
CTGG. All products were amplified for 25 cycles with the
exception of p65 which required a total of 35 cycles for
visualization. Amplified products were fractionated on 1.5%
agarose gels in 16TBE (Tris Borate-EDTA), visualized by
ethidium bromide, transferred to Nytran Plus (Schleicher &
Schuell) and hybridized with specific NF-kB/Rel probes,
radiolabeled with [a-32P]dCTP (Pharmacia BioTech). Hybri-
dizations were performed for 1 h at 688C in QuickHyb
Hybridization Solution (Stratagene) as recommended by the
manufacturer. Blots were washed once in 26SSC for 15 min
at room temperature followed by two washes in 0.16SSC for
30 min at 658C. Exposure times ranged from 1 – 2 days.
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